A 38-year-old man is being treated with isoniazid, rifampin, pyrazinamide, and ethambutol for active pulmonary tuberculosis. Four weeks into his therapy, he presents to the clinic reporting new-onset nausea, right upper quadrant abdominal discomfort, and dark urine. Physical examination reveals mild scleral icterus. Arrange the following steps for the evaluation and longitudinal management of this patient's suspected drug-induced liver injury in the correct chronological sequence.
- 1Measure serum liver transaminases and total bilirubin levels
- 2Discontinue isoniazid, rifampin, and pyrazinamide
- 3Monitor liver enzymes until they fall to less than twice the upper limit of normal
- 4Sequentially reintroduce the anti-tuberculosis medications one at a time
Answer
The correct sequence is to first measure liver transaminases, immediately discontinue the hepatotoxic agents, monitor the enzymes until they safely improve, and finally reintroduce the medications sequentially.
The standard protocol for managing symptomatic hepatotoxicity during tuberculosis treatment involves confirming the injury with laboratory tests, immediately discontinuing the likely offending agents (isoniazid, rifampin, pyrazinamide), monitoring until enzymes normalize to safe levels, and sequentially re-challenging the patient to identify the specific drug responsible.
Step-by-Step Solution
Key Concept
Management of anti-tuberculosis drug-induced hepatotoxicity requires immediate cessation of hepatotoxic drugs upon symptomatic elevation of transaminases, followed by serial monitoring and stepwise reintroduction.